Portal de Periódicos da CAPES

Needle-free and adjuvant-free epicutaneous boosting of pertussis immunity: Preclinical proof of concept

2015; Elsevier BV; Volume: 33; Issue: 30 Linguagem: Inglês

10.1016/j.vaccine.2015.05.089

1873-2518

Beatris Mastelic Gavillet, Lucie Mondoulet, Véronique Dhelft, Christiane S. Eberhardt, Floriane Auderset, Hong Thai Pham, Jean Pétré, Paul‐Henri Lambert, Pierre‐Henri Benhamou, Claire‐Anne Siegrist,

SARS-CoV-2 and COVID-19 Research

The limited durability of pertussis vaccine-induced protection requires novel approaches to reactivate immunity and limit pertussis resurgence in older children and adults. We propose that periodic boosters could be delivered using a novel epicutaneous delivery system (Viaskin) to deliver optimized pertussis antigens such as genetically-detoxified pertussis toxin (rPT). To best mimic the human situation in which vaccine-induced memory cells persist, whereas antibodies wane, we developed a novel adoptive transfer murine model of pertussis immunity. This allowed demonstrating that a single application of Viaskin delivering rPT and/or pertactin and filamentous hemagglutinin effectively reactivates vaccine-induced pertussis immunity and protects against Bordetella pertussis challenge. Recalling pertussis immunity without needles nor adjuvant may considerably facilitate the acceptance and application of periodic boosters.